May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
rTMS: A New Treatment Possibility for Amblyopia
Author Affiliations & Notes
  • B. Thompson
    McGill University, Montreal, Quebec, Canada
    Ophthalmology,
  • B. Mansouri
    McGill University, Montreal, Quebec, Canada
    Ophthalmology,
  • L. Koski
    McGill University, Montreal, Quebec, Canada
    Medicine,
  • R. F. Hess
    McGill University, Montreal, Quebec, Canada
    Ophthalmology,
  • Footnotes
    Commercial Relationships  B. Thompson, US Provisional Patent, P; B. Mansouri, US Provisional Patent, P; L. Koski, US Provisional Patent, P; R.F. Hess, US Provisional Patent, P.
  • Footnotes
    Support  CIHR MOP 53346
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2834. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. Thompson, B. Mansouri, L. Koski, R. F. Hess; rTMS: A New Treatment Possibility for Amblyopia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2834. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The purpose of this study was to test the potential of repetitive transcranial magnetic stimulation as a treatment for visual loss in amblyopia. rTMS is a non-invasive technique for modulating excitability and inhibition in the cortex. Given the cortical basis of the visual loss in amblyopia and the link between intracortical inhibition and recovery of vision in amblyopia animals, we hypothesized that rTMS may have a therapeutic effect in amblyopic humans.

Methods: : Seven adult strabismic amblyopes participated in the study. Contrast sensitivity for the amblyopic and fellow fixing eyes was tested for one high and one low spatial frequency before and after delivery of 600 pulses of 1Hz rTMS over visual cortex. The fellow fixing eye acted as a control measurement as no change in visual function was anticipated for this eye. A further control was the delivery of rTMS over motor cortex to test for non-specific effects of rTMS administration. Two participants who did not respond to the 1hz rTMS were tested with 900 pulses of 10hz rTMS (5 second trains, 45 second inter-train-interval) over visual cortex.

Results: : Five out of seven participants showed a high spatial frequency specific improvement in their amblyopic eye contrast sensitivity directly after 1hz rTMS over visual cortex and a further improvement 30 mins after rTMS administration. The remaining two participants who did not respond to 1hz rTMS did respond to 10hz rTMS administration over visual cortex with a high spatial frequency specific improvement in contrast sensitivity. No reliable changes in contrast sensitivity were found for the fellow fixing eyes and rTMS over the motor cortex had no effect on contrast sensitivity for either eye.

Conclusions: : Our initial results suggest that rTMS may be a promising treatment intervention in amblyopia. We hypothesize that the therapeutic effect is modulated by changes in cortical inhibition, however other explanations including changes in neural excitability and neural synchrony cannot currently be ruled out. The reported effects of a single dose of rTMS are transient, however repeated doses may lead to more sustained improvement. Another potentially effective application would be to combine rTMS with behavioral training régimes to optimize the therapeutic effects of perceptual training paradigms.

Keywords: amblyopia • contrast sensitivity • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×